TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of RPh201 Applied Topically for the Treatment of Hard to Heal Chronic Ulcerated Wounds

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants, either men or women are ≥ 18 years of age.~2. Patients must have at least one hard to heal wound of different etiologies (venous insufficiency, lymphatic insufficiency, neuropathic wounds or diabetic ulcers, post- operative and post-traumatic chronic wounds) located on the leg shin or foot.~3. The wound is refractive to healing at least 4 weeks prior to treatment, although treated by routine practice.~4. Wound area size is in the range of: 3 - 36 square centimeters.~5. Patients defined as grade C or above on the granulometer scale (see section 6.5.1).~6. Participants understand the nature of the procedure and provide written informed consent prior to any study procedure.~7. Women of child bearing potential must use adequate birth-control precautions.~Exclusion Criteria:~1. Clinically significant arterial vascular disease with ABI index \<0.45 if the peripheral pulse is not palpable, or flatted PVR in case of non palpable arteries.~2. Clinical evidence for presence of infection in the soft tissue, joint and/or bone (osteomyelitis).~3. Wound has Non-viable tissue which covers more than 50% of the wound area.~4. Patients with skin disorders unrelated to the ulcer that are presented adjacent to the wound.~5. The wound penetrates into deep organs and involves bone, tendon or joint~6. Wound with sinus tracts~7. Patients are receiving, or have received within one month prior to enrollment any treatment known to impair wound healing, including but not limited to: immuno-suppressive drugs, cytotoxic agents, radiation therapy and chemotherapy.~8. Treatment with a dressing containing growth factors or other biological dressings within 15 days, prior to the screening visit.~9. Patients that have a history of alcohol or drug abuse within the last two years.~10. Female patients who are pregnant or nursing, or of childbearing potential and are not using adequate contraception.~11. Participation in another clinical trial within 30 days prior to the Screening Visit or during this study.~12. Clinically significant and/or uncontrolled condition or other significant medical disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Participants must satisfy the following criteria to be enrolled in the study:~Inclusion~* Participant is ≥ 18 years of age at the time of signing the ICF.~* Participant has a history of multiple myeloma (MM) with relapsed and/or refractory disease~* Participant must have measurable disease.~* Participant has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.~Exclusion Criteria~* Participant has symptomatic central nervous system involvement of MM.~* Participant had a prior autologous stem cell transplant ≤ 3 months prior to starting CC-99712.~* Participant had a prior allogeneic stem cell transplant with either standard or reduced intensity conditioning ≤ 6 months prior to starting CC-99712 or is on systemic immunosuppression for graft-versus host disease.~* Subject is a pregnant or lactating female.~* Subject has known human immunodeficiency virus (HIV) infection.~* Subject has active hepatitis B or C (HBV/HCV) infection.~Other protocol-defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (CC-99712 monotherapy) (Type: EXPERIMENTAL): CC-99712 will be administered via intravenous (IV) infusion.
- Arm 2 (CC-99712 and BMS-986405 combination) (Type: EXPERIMENTAL): CC-99712 will be administered via IV infusion. BMS-986405 will be administered orally.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Role of the Coagulation Pathways in Recurrent Angioedema

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* recurrent angioderma~Exclusion Criteria:~* anticoagulant therapy, diseases of hemostasis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 AE-Bk (Type: OTHER): Arm of the recurring angiodeme medié by the bradykinine: blood test
- Arm 2 AE-Mast (Type: OTHER): Superficial nettle rash group recurring angiodemes associated with superficial nettle rash: blood test
- ARM 3 AEI (Type: OTHER): Arm recurring angiodemes isolate idiopathique not hostaminergique: blood test
- ARM 4 US (Type: OTHER): Arm of superficial nettle rashes: blood test

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of probable or definite ALS~* ALSFRS-R score \>25 and FVC score ≥ 60% predicted~* If currently taking Riluzole and/or Edaravone/Radicava must be on stable dose for 3 months prior to Baseline/Screening. If the dosing has not been stable for 3 months prior to Baseline/Screening or if stopped due to an adverse event, the waiting period off the medication will be 7 days. If not on either of these medications may start if desired either or both medications after enrollment into study.~Exclusion Criteria:~* Diagnosis of probable or definite ALS more than 3 years prior to study enrollment~* Diagnosis or previous history of ischemic stroke, brain tumor, uncontrolled diabetes, renal insufficiency, or severe hypertension.~* Diagnosis or previous history of comorbid progressive neurodegenerative disease such as Alzheimer's disease, Parkinson's disease, Lewy Body disease, Pick's disease, Huntington's disease, Progressive Supranuclear palsy. ALS patients diagnosed with frontotemporal dementia will not be excluded from this study.~* Diagnosis or previous history of symptomatic peripheral neuropathy. Patients with findings of peripheral neuropathy on electrodiagnostic tests only but no clinical symptoms at the time of enrollment are eligible.~* Undergoing any chemotherapy or radiation therapy for any cancer~* Any medical condition likely to interfere with the conduct of the trial or survival of the patient during this study period~* Pregnant women or women who are breast feeding~* Has taken L-Serine supplement within 30 days prior to start of study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- L-Serine (Type: EXPERIMENTAL): L-Serine 15 grams orally twice a day as tolerated for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Sitagliptin in Cystic Fibrosis-Related Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 19 years of age or older~* Cystic fibrosis-related diabetes with or without fasting hyperglycemia either untreated or using only pre-prandial repaglinide or pre-prandial bolus insulin therapy~Exclusion Criteria:~* Age under 19 years~* Use of basal insulin therapy~* Creatinine Clearance \< 50 mL/min~* Active cystic fibrosis exacerbation~* Pregnancy~* Women of child-bearing age not using effective contraception~* Current or prior use of DPPIV inhibitor

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sitagliptin (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility Study of Laser Treatment of the Crystalline Lens to Correct Presbyopia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects must sign and be given a copy of the written informed consent form.~* Subjects must have elected to undergo lens extraction and IOL implantation to treat their ocular disorder then elect to have the LensAR laser surgery as part of the procedure.~* Cataract should not exceed LOCS III Grade 2.~* Subjects must have best corrected distance visual acuity of 20/40 or better in the eye to be treated .~* Subjects must be ≥ 45 years and ≤ 60 years of age at time of subject eligibility visit.~* Subjects must be willing and able to return for scheduled follow up examinations for 6 months after cataract surgery or up to 3 years (at 6 month intervals) if no cataract surgery is performed.~* Subject must have central 7 mm of clear cornea without vascularization~Exclusion Criteria:~* Subjects who are pregnant, lactating, or planning to become pregnant during the course of the study.~* Subjects who have undergone previous corneal or intraocular surgery in the eye to be treated.~* Subjects with a history, signs or symptoms of ocular disease or atypical finding which would be contraindicated under standard of care for cataract surgery.~* Diabetic or hypertensive subjects with clinical evidence of retinal pathology.~* Subjects with macular degenerative pathology.~* Subjects with a history of steroid-responsive rise in IOP or uncontrolled glaucoma in either eye.~* Subjects with known lens/zonular instability such as, but not restricted to, Marfan's Syndrome, Pseudoexfoliation Syndrome, etc.~* Subjects with corneal disease or pathology that precludes applanation of the cornea or transmission of laser wavelength or distortion of laser light.~* Subjects who cannot attain ocular dilation adequate to allow laser treatment within the minimum range based on the laser procedure to be applied.~* Subjects with known sensitivity to planned study concomitant medications.~* Subjects using systemic medication that is known to reduce the amplitude of accommodation (such as medication for motion sickness containing hyoscine or other antimuscarinic drugs, anticholinergic drugs, anti-psychotic drugs, tricyclic antidepressants and other drugs acting on the central nervous system).~* Subjects participating in any other ophthalmic drug or device clinical trial during the time of this clinical investigation.

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: TXA in Revision Total Shoulder Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients older than 18 years old~2. Patients younger than 90 years old~3. Patients undergoing scheduled revision total shoulder arthroplasty~4. Patients who consent to be randomized~Exclusion Criteria:~1. Patients younger than 18~2. Patients older than 90 years old~3. Patients who are pregnant or breast-feeding women~4. Patients who are allergic to tranexamic acid~5. Patients with proximal humerus fracture or fracture sequelae~6. Patients who use estrogen containing medications (i.e. oral contraceptive pills)~7. Patients who have acquired disturbances of color vision~8. Patients with a history of any of the following diagnosis: '~   * Subarachnoid hemorrhage~  * Active intravascular clotting~  * Severe pulmonary disease (FEV \<50% normal)~  * Plasma creatinine \> 115 μmol/L in males, \> 100 μmol/L in females, or hepatic failure)~  * (Renal impairment serum creatinine \> 1.5 times the upper limit of normal NYU)~  * Preoperative anemia \[Hemoglobin (Hb) \< 11g/dL in females, Hb \< 12 g/dL in males\]~9. Patients who refuse blood products~10. Patients undergoing hormone replacement therapy~11. Patients with diagnosed or self-reported cognitive dysfunction;~12. Patients who are unable to understand or follow instructions;~13. Patients with severe liver disease, renal insufficiency, congestive heart failure, and/or significant heart disease;~14. Patients with BMI over 50~15. Any patient that the investigators feel cannot comply with all study related procedures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Tranexamic acid (TXA) Injection (Type: EXPERIMENTAL): Participants scheduled for Revision Total Shoulder Arthroplasty (TSA) will receive two injections of TXA.
- Control - No Tranexamic acid (TXA) Injection (Type: NO_INTERVENTION): Participants scheduled for Revision Total Shoulder Arthroplasty (TSA) won't receive any injections TXA.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have histologically or cytologically confirmed incurable SCLC and have had prior treatment with platinum-based chemotherapy. High-grade neuroendocrine tumors that are suspected to be of bronchopulmonary origin can be enrolled if they have had prior treatment with a SCLC chemotherapy regimen (e.g. platinum plus etoposide).~* Patients should not be demonstrating end-organ damage due to rapid progression of disease based on the most recent assessment of the treating physician.~* Patients must have radiographically measurable metastatic disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria.~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.~* Absolute neutrophil count \>= 1,500/mcL.~* Platelets \>= 100,000/mcL.~* Chemotherapy agents are known to be teratogenic, therefore women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.~* Ability to understand and the willingness to sign an Institutional Review Board (IRB)-approved informed consent document.~Exclusion Criteria:~* Patients who have previously received either gemcitabine or an immune checkpoint inhibitor can be enrolled.~* Emergent need for palliative radiation.~* Patients may not be receiving any other investigational agents for the treatment of nonsmall cell lung cancer.~* History of allergic reaction to gemcitabine.~* Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.~* Pregnant women are excluded from this study because of the potential for teratogenic or abortifacient effects with chemotherapy. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with chemotherapy, breastfeeding should be discontinued.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (gemcitabine, nivolumab) (Type: EXPERIMENTAL): Participants receive gemcitabine IV over 30 minutes and nivolumab IV over 60 minutes on day 1. Treatment repeats every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Two Treatment Strategies in Patients With an Acute Coronary Syndrome Without ST Elevation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* High risk ACS without ST elevation~Exclusion Criteria:~* Age \<18 years~* Pregnancy~* Persistence of the ST elevation~* Recent left branch block~* Cardiac failure or cardiogenic shock (Kilip 3 or 4)~* Treatment by anti-vitamin K~* Contra-indication to the use of one of the following treatments: aspirin, clopidogrel, enoxaparine, anti GP IIb/IIIa (tirofiban)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Early Invasive strategy (Type: EXPERIMENTAL): Tirofiban and coronarography within 6 hours
- Delayed invasive strategy (Type: ACTIVE_COMPARATOR): Coronarography after 6 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: ISABel: Intelligent Sleep Apnoea Bed

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Documented supine positional OSA (AHIsupine/AHInonsupine ≥2) with a total AHI of ≥10 events/hour~* Age ≥18 years and \<80 years~* Written informed consent documented by signature~Exclusion Criteria:~* Previous or current use of positional therapy~* Use of home oxygen therapy~* Documented hypoventilation syndrome~* Documented Cheyne-Stokes breathing~* Documented moderate-to-severe or severe obstructive lung diseases~* Chronic heart failure~* Documented active drug or alcohol abuse~* Known or suspected non-compliance~* Inability to follow the procedures of the study, e.g. due to language problems, documented psychological disorders, documented dementia, etc. of the participant~* Current professional driver or any either documented or reported previous sleep-related driving accidents~* People working with or operating heavy machinery~* Child-bearing age: female participants who are neither surgically sterilised / hysterectomised nor post-menopausal for longer than 2 years are considered as being of child bearing potential~* Documented unstable, untreated coronary or peripheral artery disease, severe hypertension or hypotension (≥180/110 or ≤90/60 mmHg)~* BMI \>40 kg/m2 or body weight \>130 kg~* Being the investigator, his/her family members, employees, or other dependent persons

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ISABel Bed 1 or ISABel Bed 2 (Type: OTHER): The study has a within-subject repeated measures-design. After a baseline measurement, participants will be allocated to either a first experimental night in automated bed 1 (ISABel Bed 1) and a second one in automated bed 2 (ISABel Bed 2) or a first experimental night in bed 2 and a second one in bed 1. Afterwards, the results of each polysomnographic measurement carried out during the intervention will be compared to the off-treatment baseline measurement.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: 18F-FluorThanatrace (PET/CT) in Glioblastoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants will be ≥ 22 years of age~2. Participants will have a diagnosis of glioblastoma and be enrolled in the companion treatment trial, IRB 832694.~3. Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.~Exclusion Criteria:~1. Females who are pregnant or breast-feeding at the time of screening will not be eligible for this study; a urine pregnancy test will be performed in women of childbearing potential at screening.~2. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician.~Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Non-surgical candidates (Type: OTHER): In this arm, subjects that do not have a clinical indication for surgical resection of the recurrent tumor will start TTFields therapy 5-7 days prior to starting oral niraparib (a PARP inhibitor).
- Surgical candidates (Type: OTHER): In this arm, subjects who have a clinical indication for surgical resection of the recurrent tumor will receive TTFields therapy for 5-7 days prior to planned surgical resection, undergo resection, and then resume TTFields therapy and initiate niraparib post-operatively.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy